Who are Ftivazid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Merital, Isoniazid, Cadral, L-Tryptophan, Sulide, Circadin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ftivazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ftivazid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ftivazid (FTIVAZIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ftivazide. Area: Infectious Disease.

phase 2 ftivazide Myeloperoxidase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ftivazid (FTIVAZIDE). Ftivazid works by inhibiting the activity of myeloperoxidase, an enzyme that contributes to the development of tuberculosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ftivazid TARGET	FTIVAZIDE		phase 2	ftivazide	Myeloperoxidase
Merital	NOMIFENSINE		marketed	nomifensine	Hemoglobin HbA, Myeloperoxidase, 5-hydroxytryptamine receptor 1A	1984-01-01
Isoniazid	ISONIAZID	Epic Pharma Llc	marketed	Antimycobacterial [EPC]	Myeloperoxidase	1952-01-01
Cadral	CADRALAZINE		marketed	cadralazine	Myeloperoxidase, Voltage-dependent L-type calcium channel subunit alpha-1C
L-Tryptophan	TRYPTOPHAN		marketed	tryptophan	Myeloperoxidase, Extracellular calcium-sensing receptor, Probable G-protein coupled receptor 139
Sulide	NIMESULIDE		marketed	nimesulide	Myeloperoxidase, Aromatase, Interstitial collagenase
Circadin	Circadin	Neurim Pharmaceuticals Ltd.	marketed		Cytochrome P450 1B1, Myeloperoxidase, Nuclear receptor ROR-alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ftivazide class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ftivazid — Competitive Intelligence Brief. https://druglandscape.com/ci/ftivazide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing